Je-Young Park, Owen Sunga, Rungsima Wanitphakdeedecha, Jürgen Frevert
Special Topic
Je-Young Park, Owen Sunga, Rungsima Wanitphakdeedecha, Jürgen Frevert
Recently launched esthetic botulinum toxin serotype A (BoNT/A) products include Nabota/Jeuveau, Meditoxin/Neuronox, and Botulax, which contain nontoxic accessory proteins and excipients. Clinical evidence supporting these formulations, including their purity and potential immunogenicity or their link to treatment failures, is limited. Any nonhuman protein, including nontoxin accessory proteins, can initiate immune reactions, especially if administered repeatedly, yet the issue of BoNT/A- induced immunogenicity is widely contested.
Official website: Neurotoxin Impurities: A Review of Threats to Efficacy
Sign in or register for free to read the full article
Share: